Control mice that received healthy cartilage in both flanks showed little damage, as did mice that received implants of fibroblasts from patients with osteoarthritis, which does not spread from joint to joint.
However, Baumans et al. [ 25] found significant changes in behavior, feeding, and body mass in laboratory mice that received implants of 12% of body mass, though part of the observed changes were in response to the surgery.
Treatment of mice that had received implants of E2 pellets at 1 month of age with bromocriptine (dopamine agonist) from 6 months of age decreased serum levels of prolactin, and was accompanied by an increase in the incidence of nodules.
Since E2 increases serum levels of prolactin, high serum levels of prolactin in mice that have received implants of E2 pellets may play a role in the suppression of hepatocellular tumorigenesis.
Mice were divided into two group: one received corticosterone implants of 30 mg (Innovative Research of America, Sarasota, FL) (n = 8), while the other mice received placebo implants (Innovative Research of America, Sarasota, FL) (n = 8).
Bilateral ovariectomy was performed at 4 weeks of age, and concomitantly the mice received pellets implanted subcutaneously releasing either placebo, E2 (17β-estradiol 0.1 mg, 60 days release, i.e., 80 μg/kg/day, Innovative Research of America, Sarasota, FL) or an osmotic minipump releasing E4 (1 or 6 mg/kg/day).
In the SCID-hu model, SCID mice first receive implants of a human fetal bone chip, followed by injections of MM cells directly into human fetal bone grafts.
He received implants for his knees in 2005.
